2019
DOI: 10.1634/theoncologist.2018-0823
|View full text |Cite
|
Sign up to set email alerts
|

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

Abstract: Background The objective of this study was to characterize the clinicopathologic features of sicca syndrome associated with immune checkpoint inhibitor (ICI) therapy. Subjects, Materials, and Methods Consecutive patients with new or worsening xerostomia in the setting of ICI treatment for benign or malignant neoplastic disease were evaluated, including labial salivary gland biopsy (LSGB). Results Twenty patients (14 male; median age 57 years) had metastatic melanoma (n = 10), metastatic carcinoma (n = 6), or r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
154
1
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 140 publications
(164 citation statements)
references
References 38 publications
8
154
1
1
Order By: Relevance
“…Patients who do not respond to corticosteroids or who have recurring immune‐related colitis following a corticosteroid taper may require treatment with the antitumor necrosis factor‐α antibody infliximab. As noted above, published guidelines describing irAEs are focused on toxicity secondary to CTLA‐4 and PD‐1/L1 monotherapies or to the concurrent administration of both types of ICIs. Since co‐administration of another type of therapy (e.g., chemotherapy with a PD‐1/L1 inhibitor) may confound the diagnosis of immune‐related colitis and lead to the delay of a suitable remedy, current immunotherapy management guidelines should be applied judiciously.…”
Section: Case In Point: An Immune‐related Adverse Event With Pd‐1/l1 mentioning
confidence: 99%
See 2 more Smart Citations
“…Patients who do not respond to corticosteroids or who have recurring immune‐related colitis following a corticosteroid taper may require treatment with the antitumor necrosis factor‐α antibody infliximab. As noted above, published guidelines describing irAEs are focused on toxicity secondary to CTLA‐4 and PD‐1/L1 monotherapies or to the concurrent administration of both types of ICIs. Since co‐administration of another type of therapy (e.g., chemotherapy with a PD‐1/L1 inhibitor) may confound the diagnosis of immune‐related colitis and lead to the delay of a suitable remedy, current immunotherapy management guidelines should be applied judiciously.…”
Section: Case In Point: An Immune‐related Adverse Event With Pd‐1/l1 mentioning
confidence: 99%
“…Although further study is needed, recent reports highlight the potential detrimental effect on anticancer response of high‐dose steroids at the onset or during PD‐1/L1 inhibitor treatment and thus the need to continue to refine treatment algorithms for irAEs based on available evidence. Similar to the approach used for PD‐1/L1 inhibitor monotherapy , the diagnosis and management of irAEs in patients receiving combination therapy will require an integrated team of oncologists and specialists.…”
Section: Immune‐related Adverse Events With Pd‐1/l1 Inhibitor Combinamentioning
confidence: 99%
See 1 more Smart Citation
“…A number of studies have reported the association of PD‐1 inhibitors with oral lichenoid reactions (Schaberg et al, ; Shi et al, ; Sibaud et al, ), SJS (Saw et al, ), toxic epidermal necrolysis (TEN) (Nayar et al, ), bullous pemphigoid (Jour et al, ), EM (Utsunomiya et al, ), and sicca syndrome (Cappelli et al, ; Teyssonneau, Cousin, & Italiano, ; Warner et al, ). Nevertheless, further characterization of oral lesions and management outcomes warrants study.…”
Section: Discussionmentioning
confidence: 99%
“…EM (Utsunomiya et al, 2018), and sicca syndrome (Cappelli et al, 2017;Teyssonneau, Cousin, & Italiano, 2017;Warner et al, 2019).…”
Section: Discussionmentioning
confidence: 99%